Welireg (Belzutifan)

Welireg (belzutifan) is a first-in-class, oral HIF-2α (hypoxia-inducible factor-2 alpha) inhibitor from Merck. It is approved for adults with Von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET) not requiring immediate surgery.

Welireg is also approved for adults with advanced RCC with a clear cell component, following a PD-1/PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor (VEGF-TKI), and for adults and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL).

Certain tumors accumulate abnormally high levels of HIF-2α, which drives angiogenesis and tumor growth. Belzutifan binds HIF-2α and blocks this pathway, slowing tumor progression.

• Anemia can be severe; hemoglobin should be monitored before starting treatment and periodically thereafter.
• Hypoxia: oxygen saturation should be monitored throughout treatment; therapy may need to be withheld or discontinued for significant drops.
• Embryo-fetal toxicity: Welireg can cause fetal harm. Effective non-hormonal contraception is required during treatment and for one week after the final dose.
• Common side effects include anemia, fatigue, headache, dizziness, nausea, and increased blood glucose or creatinine.

What documents are required to import Welireg to India?

Welireg may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a qualified oncologist
• The patient’s diagnostic reports
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription from the doctor and an import permit, if applicable.

Is Welireg available in India?

Welireg is a prescription medicine that legally requires a doctor’s prescription to be dispensed. It is not commercially marketed in India. However, patients in India can legally access Welireg through the Named Patient Program (NPP), an import provision that allows a medicine not yet registered in India to be imported for an individual patient’s personal treatment.

Indian Pharma Network (IPN) can source Welireg from reliable channels across the world and facilitate supply to patients, doctors, and hospitals, offering worldwide access to this treatment under applicable legal provisions. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the patient’s address from New Delhi, India, after legal requirements are fulfilled.

For Welireg cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• United States: Approved by the FDA — August 13, 2021 (initial approval), with expanded indications through 2023-2026.

What is the generic name for the brand drug Welireg?

Belzutifan is the generic name for the brand drug Welireg.

What is Welireg used for?

Welireg is used to treat tumors associated with Von Hippel-Lindau (VHL) disease, advanced renal cell carcinoma (RCC), and pheochromocytoma or paraganglioma (PPGL).

Who manufactures Welireg?

Welireg is manufactured by Merck & Co., Inc. (known as MSD outside the United States and Canada).

What type of medicine is Welireg?

Welireg is a first-in-class oral HIF-2α (hypoxia-inducible factor-2 alpha) inhibitor.

Is Welireg approved by the FDA?

Yes. Welireg received initial US FDA approval on August 13, 2021, with additional indications approved through 2023-2026.

How much does Welireg cost in India?

Price depends on sourcing country, exchange rate, quantity, customs duty, and logistics. Share your prescription with IPN’s patient support team for a transparent, itemized quote.